药品详细
Mitomycin (丝裂霉素 )
化学结构式图
中文名
丝裂霉素
英文名
Mitomycin
分子式
Not Available
化学名
[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate
分子量
Average: 334.3272
Monoisotopic: 334.127719706
Monoisotopic: 334.127719706
CAS号
50-07-7
ATC分类
L01D 细胞毒素抗生素及相关物质
药物类型
small molecule
阶段
商品名
Ametycin;Ametycine;Mit-C;Mito-C;Mitocin-C;Mitomycin (TN);Mitomycin C;Mitomycin-C;Mitomycinum;Mitomycinum C;Mitomycyna C [Polish];Mitozytrex;Muamycin;Mutamycin;Mytomycin;Mytozytrex;
同义名
7-Amino-9α-methoxymitosane;Mitamycin;MMC;
基本介绍
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
生产厂家
- Accord healthcare inc
- Baxter healthcare corp anesthesia and critical care
- Bedford laboratories div ben venue laboratories inc
- Bristol laboratories inc div bristol myers co
- Bristol myers co
- Hospira inc
- Supergen inc
封装厂家
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
| Form | Route | Strength |
|---|---|---|
| Powder, for solution | Intravesical |
规格
| Unit description | Cost | Unit |
|---|---|---|
| Mutamycin 40 mg vial | 878.48 USD | vial |
| Mutamycin 20 mg vial | 434.8 USD | vial |
| Mitomycin 40 mg vial | 300.0 USD | vial |
| Mitomycin 20 mg vial | 142.55 USD | vial |
| Mutamycin 5 mg vial | 128.75 USD | vial |
| Mitomycin 5 mg vial | 52.43 USD | vial |
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
Cancer 癌症;
药理
| Indication | For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. |
| Pharmacodynamics | Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. |
| Mechanism of action | Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific. |
| Absorption | Erratic. |
| Volume of distribution | Not Available |
| Protein binding | Not Available |
| Metabolism |
Primarily hepatic, some in various other tissues. |
| Route of elimination | Approximately 10% of a dose of mitomycin is excreted unchanged in the urine. |
| Half life | 8-48 min |
| Clearance | Not Available |
| Toxicity | Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting. |
| Affected organisms |
|
| Pathways | Not Available |
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||
| Melting point | > 360 oC | ||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Trastuzumab | Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. |
| Vinblastine | Potentially severe lung toxicity |
| Vincristine | Potentially severe lung toxicity |
| Vindesine | Potentially severe lung toxicity |
食物相互作用
Not Available
收藏